6-month consequences of COVID-19 in patients discharged from hospital: a cohort study - PubMed (original) (raw)
. 2021 Jan 16;397(10270):220-232.
doi: 10.1016/S0140-6736(20)32656-8. Epub 2021 Jan 8.
Lixue Huang 2, Yeming Wang 3, Xia Li 4, Lili Ren 5, Xiaoying Gu 6, Liang Kang 1, Li Guo 5, Min Liu 7, Xing Zhou 4, Jianfeng Luo 4, Zhenghui Huang 4, Shengjin Tu 4, Yue Zhao 8, Li Chen 8, Decui Xu 8, Yanping Li 8, Caihong Li 8, Lu Peng 8, Yong Li 3, Wuxiang Xie 9, Dan Cui 10, Lianhan Shang 11, Guohui Fan 6, Jiuyang Xu 12, Geng Wang 13, Ying Wang 5, Jingchuan Zhong 5, Chen Wang 14, Jianwei Wang 5, Dingyu Zhang 1, Bin Cao 15
Affiliations
- PMID: 33428867
- PMCID: PMC7833295
- DOI: 10.1016/S0140-6736(20)32656-8
6-month consequences of COVID-19 in patients discharged from hospital: a cohort study
Chaolin Huang et al. Lancet. 2021.
Retracted and republished in
- Retraction and republication: 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study.
The Lancet Editors. The Lancet Editors. Lancet. 2023 Jun 17;401(10393):2025. doi: 10.1016/S0140-6736(23)01175-3. Epub 2023 Jun 9. Lancet. 2023. PMID: 37307841 Free PMC article. Retracted and republished. No abstract available.
Expression of concern in
- Expression of concern: 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study.
The Lancet Editors. The Lancet Editors. Lancet. 2023 Jan 14;401(10371):90. doi: 10.1016/S0140-6736(22)02370-4. Epub 2022 Nov 24. Lancet. 2023. PMID: 36436530 Free PMC article. No abstract available.
Abstract
Background: The long-term health consequences of COVID-19 remain largely unclear. The aim of this study was to describe the long-term health consequences of patients with COVID-19 who have been discharged from hospital and investigate the associated risk factors, in particular disease severity.
Methods: We did an ambidirectional cohort study of patients with confirmed COVID-19 who had been discharged from Jin Yin-tan Hospital (Wuhan, China) between Jan 7, 2020, and May 29, 2020. Patients who died before follow-up, patients for whom follow-up would be difficult because of psychotic disorders, dementia, or re-admission to hospital, those who were unable to move freely due to concomitant osteoarthropathy or immobile before or after discharge due to diseases such as stroke or pulmonary embolism, those who declined to participate, those who could not be contacted, and those living outside of Wuhan or in nursing or welfare homes were all excluded. All patients were interviewed with a series of questionnaires for evaluation of symptoms and health-related quality of life, underwent physical examinations and a 6-min walking test, and received blood tests. A stratified sampling procedure was used to sample patients according to their highest seven-category scale during their hospital stay as 3, 4, and 5-6, to receive pulmonary function test, high resolution CT of the chest, and ultrasonography. Enrolled patients who had participated in the Lopinavir Trial for Suppression of SARS-CoV-2 in China received severe acute respiratory syndrome coronavirus 2 antibody tests. Multivariable adjusted linear or logistic regression models were used to evaluate the association between disease severity and long-term health consequences.
Findings: In total, 1733 of 2469 discharged patients with COVID-19 were enrolled after 736 were excluded. Patients had a median age of 57·0 (IQR 47·0-65·0) years and 897 (52%) were men. The follow-up study was done from June 16, to Sept 3, 2020, and the median follow-up time after symptom onset was 186·0 (175·0-199·0) days. Fatigue or muscle weakness (63%, 1038 of 1655) and sleep difficulties (26%, 437 of 1655) were the most common symptoms. Anxiety or depression was reported among 23% (367 of 1617) of patients. The proportions of median 6-min walking distance less than the lower limit of the normal range were 24% for those at severity scale 3, 22% for severity scale 4, and 29% for severity scale 5-6. The corresponding proportions of patients with diffusion impairment were 22% for severity scale 3, 29% for scale 4, and 56% for scale 5-6, and median CT scores were 3·0 (IQR 2·0-5·0) for severity scale 3, 4·0 (3·0-5·0) for scale 4, and 5·0 (4·0-6·0) for scale 5-6. After multivariable adjustment, patients showed an odds ratio (OR) 1·61 (95% CI 0·80-3·25) for scale 4 versus scale 3 and 4·60 (1·85-11·48) for scale 5-6 versus scale 3 for diffusion impairment; OR 0·88 (0·66-1·17) for scale 4 versus scale 3 and OR 1·77 (1·05-2·97) for scale 5-6 versus scale 3 for anxiety or depression, and OR 0·74 (0·58-0·96) for scale 4 versus scale 3 and 2·69 (1·46-4·96) for scale 5-6 versus scale 3 for fatigue or muscle weakness. Of 94 patients with blood antibodies tested at follow-up, the seropositivity (96·2% vs 58·5%) and median titres (19·0 vs 10·0) of the neutralising antibodies were significantly lower compared with at the acute phase. 107 of 822 participants without acute kidney injury and with estimated glomerular filtration rate (eGFR) 90 mL/min per 1·73 m2 or more at acute phase had eGFR less than 90 mL/min per 1·73 m2 at follow-up.
Interpretation: At 6 months after acute infection, COVID-19 survivors were mainly troubled with fatigue or muscle weakness, sleep difficulties, and anxiety or depression. Patients who were more severely ill during their hospital stay had more severe impaired pulmonary diffusion capacities and abnormal chest imaging manifestations, and are the main target population for intervention of long-term recovery.
Funding: National Natural Science Foundation of China, Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences, National Key Research and Development Program of China, Major Projects of National Science and Technology on New Drug Creation and Development of Pulmonary Tuberculosis, and Peking Union Medical College Foundation.
Copyright © 2021 Elsevier Ltd. All rights reserved.
Figures
Figure 1
Flow chart of patients with COVID-19 discharged from Jin Yin-tan Hospital between Jan 7, and May 29, 2020 HRCT=high resolution CT. LOTUS= Lopinavir Trial for Suppression of SARS-CoV-2 in China. *A series of questionnaires included a self-reported symptom questionnaire, the modified British Medical Research Council dyspnoea scale, the EuroQol five-dimension five-level questionnaire, the EuroQol Visual Analogue Scale, and an ischaemic stroke and cardiovascular event registration form. †Laboratory tests included a white cell count, lymphocyte count, serum creatinine, haemoglobin, and glycosylated haemoglobin.
Figure 2
Risk factors associated with diffusion impairment and CT score (A), and anxiety or depression and fatigue or muscle weakness (B) For associations of age, cigarette smoking, and education with outcome measure, the variables including age, gender, cigarette smoking, education, comorbidity, corticosteroids, antivirals, and intravenous immunoglobulin were all included in the models. For association of comorbidity with outcome, the aforementioned variables were all included together with comorbidity. For association of other factors including sex, corticosteroid, antiviral, and intravenous immunoglobulin with outcome, disease severity and the aforementioned variables were included in the model. OR (95% CI) or β (95% CI) for age indicates the risk of diffusion impairment, CT score, anxiety or depression, and fatigue or muscle weakness per 10-year age increase. OR=odds ratio.
Figure 3
Temporal changes of seropositivity and antibody titres against SARS-CoV-2 (A) Seropositivity of each antibody indicated by the y-axis. Violin plots show the distribution of each antibody feature N (B), RBD (C), S (D), and neutralising antibodies (E) split across baseline and follow-up plasma samples of 94 individuals. The horizontal lines are used to indicate the value used to diagnose positivity from the antibody test. The comparison of antibody test results at acute phase and follow-up was done with paired_t_ tests for antibody titres and McNemar test for antibody positive rates. Plasma samples at acute phase were collected during hospital stay with a median duration of 23 (IQR 20–26) days from illness onset. OD=optical density. SARS-CoV-2=severe acute respiratory syndrome coronavirus 2. p values indicate a comparison between acute phase and follow-up. *p<0·0001. †p=0·29. ‡p=0·039. §p=1·00. ¶p=0·021.
Comment in
- Long-term follow-up of recovered patients with COVID-19.
Cortinovis M, Perico N, Remuzzi G. Cortinovis M, et al. Lancet. 2021 Jan 16;397(10270):173-175. doi: 10.1016/S0140-6736(21)00039-8. Epub 2021 Jan 8. Lancet. 2021. PMID: 33428868 Free PMC article. No abstract available. - Long-haul COVID: heed the lessons from other infection-triggered illnesses.
Aucott JN, Rebman AW. Aucott JN, et al. Lancet. 2021 Mar 13;397(10278):967-968. doi: 10.1016/S0140-6736(21)00446-3. Epub 2021 Mar 5. Lancet. 2021. PMID: 33684352 Free PMC article. No abstract available. - Anesthesia and the "post-COVID syndrome": Perioperative considerations for patients with prior SARS-CoV-2 infection.
Hoyler MM, White RS, Tam CW, Thalappillil R. Hoyler MM, et al. J Clin Anesth. 2021 Sep;72:110283. doi: 10.1016/j.jclinane.2021.110283. Epub 2021 Apr 8. J Clin Anesth. 2021. PMID: 33857843 Free PMC article. No abstract available. - Six-month respiratory outcomes and exercise capacity of COVID-19 acute respiratory failure patients treated with continuous positive airway pressure.
Damanti S, Ramirez GA, Bozzolo EP, Rovere-Querini P, De Lorenzo R, Magnaghi C, Scotti R, Di Lucca G, Marinosci A, Strada S, Di Terlizzi G, Vitali G, Martinenghi S, Compagnone N, Landoni G, Tresoldi M. Damanti S, et al. Intern Med J. 2021 Nov;51(11):1810-1815. doi: 10.1111/imj.15345. Intern Med J. 2021. PMID: 33961728 Free PMC article. - Long-term effects of COVID-19 on kidney function.
Enghard P, Hardenberg JH, Stockmann H, Hinze C, Eckardt KU, Schmidt-Ott KM. Enghard P, et al. Lancet. 2021 May 15;397(10287):1806-1807. doi: 10.1016/S0140-6736(21)00880-1. Lancet. 2021. PMID: 33992141 Free PMC article. No abstract available. - Long-term effects of COVID-19 on kidney function.
Delanaye P, Huart J, Bouquegneau A, Jouret F. Delanaye P, et al. Lancet. 2021 May 15;397(10287):1807. doi: 10.1016/S0140-6736(21)00881-3. Lancet. 2021. PMID: 33992143 Free PMC article. No abstract available.
Similar articles
- 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study.
Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, Kang L, Guo L, Liu M, Zhou X, Luo J, Huang Z, Tu S, Zhao Y, Chen L, Xu D, Li Y, Li C, Peng L, Li Y, Xie W, Cui D, Shang L, Fan G, Xu J, Wang G, Wang Y, Zhong J, Wang C, Wang J, Zhang D, Cao B. Huang C, et al. Lancet. 2023 Jun 17;401(10393):e21-e33. doi: 10.1016/S0140-6736(23)00810-3. Epub 2023 Jun 12. Lancet. 2023. PMID: 37321233 Free PMC article. - 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study.
Huang L, Yao Q, Gu X, Wang Q, Ren L, Wang Y, Hu P, Guo L, Liu M, Xu J, Zhang X, Qu Y, Fan Y, Li X, Li C, Yu T, Xia J, Wei M, Chen L, Li Y, Xiao F, Liu D, Wang J, Wang X, Cao B. Huang L, et al. Lancet. 2021 Aug 28;398(10302):747-758. doi: 10.1016/S0140-6736(21)01755-4. Lancet. 2021. PMID: 34454673 Free PMC article. - Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study.
Huang L, Li X, Gu X, Zhang H, Ren L, Guo L, Liu M, Wang Y, Cui D, Wang Y, Zhang X, Shang L, Zhong J, Wang X, Wang J, Cao B. Huang L, et al. Lancet Respir Med. 2022 Sep;10(9):863-876. doi: 10.1016/S2213-2600(22)00126-6. Epub 2022 May 11. Lancet Respir Med. 2022. PMID: 35568052 Free PMC article. - Prevalence of post-acute COVID-19 syndrome symptoms at different follow-up periods: a systematic review and meta-analysis.
Alkodaymi MS, Omrani OA, Fawzy NA, Shaar BA, Almamlouk R, Riaz M, Obeidat M, Obeidat Y, Gerberi D, Taha RM, Kashour Z, Kashour T, Berbari EF, Alkattan K, Tleyjeh IM. Alkodaymi MS, et al. Clin Microbiol Infect. 2022 May;28(5):657-666. doi: 10.1016/j.cmi.2022.01.014. Epub 2022 Feb 3. Clin Microbiol Infect. 2022. PMID: 35124265 Free PMC article. Review. - Maternal and infant outcomes of full-term pregnancy combined with COVID-2019 in Wuhan, China: retrospective case series.
Chen Y, Bai J. Chen Y, et al. Arch Gynecol Obstet. 2020 Sep;302(3):545-551. doi: 10.1007/s00404-020-05573-8. Epub 2020 Jul 21. Arch Gynecol Obstet. 2020. PMID: 32696241 Free PMC article. Review.
Cited by
- Long COVID at 3 and 6 months after covid-19 infection in Thailand.
Rutjanawech S, Sritipsukho P, Sritipsukho S. Rutjanawech S, et al. Sci Rep. 2024 Oct 8;14(1):23441. doi: 10.1038/s41598-024-75233-3. Sci Rep. 2024. PMID: 39379681 - FOLLOW-UP OF PATIENTS WITH POST COVID-19 CONDITION AFTER A MULTIDISCIPLINARY TEAM ASSESSMENT: A PILOT STUDY.
Wigge A, Philipson J, Hällgren S, Filipsson H, Stålnacke BM. Wigge A, et al. J Rehabil Med Clin Commun. 2024 Sep 23;7:24581. doi: 10.2340/jrm-cc.v7.24581. eCollection 2024. J Rehabil Med Clin Commun. 2024. PMID: 39351121 Free PMC article. - Neuroimaging evaluations of olfactory, gustatory, and neurological deficits in patients with long-term sequelae of COVID-19.
Masala C, Porcu M, Orofino G, Defazio G, Pinna I, Solla P, Ercoli T, Suri JS, Spinato G, Saba L. Masala C, et al. Brain Imaging Behav. 2024 Sep 28. doi: 10.1007/s11682-024-00936-0. Online ahead of print. Brain Imaging Behav. 2024. PMID: 39340624 - Health-Related Physical Fitness and Biochemical Parameters in Overweight Older People during Social Isolation Imposed by the COVID-19 Pandemic: A Longitudinal and Observational Study.
Marques MGS, Branco BHM, Marques DCS, Lalucci MPPS, Perli VAS, Nascimento JRAD Jr, Valdés-Badilla P, Oliveira DV. Marques MGS, et al. Int J Environ Res Public Health. 2024 Aug 31;21(9):1161. doi: 10.3390/ijerph21091161. Int J Environ Res Public Health. 2024. PMID: 39338044 Free PMC article. - A Blood Supply Pathophysiological Microcirculatory Mechanism for Long COVID.
Koutsiaris AG. Koutsiaris AG. Life (Basel). 2024 Aug 28;14(9):1076. doi: 10.3390/life14091076. Life (Basel). 2024. PMID: 39337860 Free PMC article.
References
- Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;324:782–793. - PubMed
- Cevik M, Kuppalli K, Kindrachuk J, Peiris M. Virology, transmission, and pathogenesis of SARS-CoV-2. BMJ. 2020;371 - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous